PT  - JOURNAL ARTICLE
AU  - Aimee M. Deaton
AU  - Margaret M. Parker
AU  - Lucas D. Ward
AU  - Alexander O. Flynn-Carroll
AU  - Lucas BonDurant
AU  - Gregory Hinkle
AU  - Paul Nioi
TI  - Gene-level analysis of rare variants in 363,977 whole exome sequences reveals an association of <em>GIGYF1</em> loss of function with diabetes
AID  - 10.1101/2021.01.19.21250105
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.19.21250105
4099  - http://medrxiv.org/content/early/2021/01/25/2021.01.19.21250105.short
4100  - http://medrxiv.org/content/early/2021/01/25/2021.01.19.21250105.full
AB  - Sequencing of large cohorts offers an unprecedented opportunity to identify rare genetic variants and to find novel contributors to human disease. We used gene-based collapsing tests to identify genes associated with glucose, HbA1c and T2D diagnosis in 363,977 exome-sequenced participants in the UK Biobank. We identified known associations with diabetes including variants in GCK, HNF1A and PDX1, genes involved in Mendelian forms of diabetes. Novel associations were identified for GIGYF1 predicted loss of function (pLOF), TNRC6B pLOF and PFAS predicted damaging missense variants. Multiple rare variants contributed to these associations, including singleton variants. The most significant novel associations were seen for GIGYF1 pLOF which associated with increased levels of glucose (0.77 mmol/L increase, p = 4.42 × 10−12) and HbA1c (4.33 mmol/mol, p = 1.28 × 10−14) as well as T2D diagnosis (OR = 4.15, p= 6.14 x10−11). GIGYF1 pLOF also associated with decreased cholesterol levels as well as an increased risk of hypothyroidism. An independent common variant association for glucose and T2D was identified at GIGYF1 which replicated in additional datasets. Our results highlight the role of GIGYF1 in regulating insulin signaling and protecting from diabetes.Competing Interest StatementAll authors are employees and stockholders of Alnylam Pharmaceuticals.Funding StatementThis study was funded by Alnylam Pharmaceuticals. No external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Advarra IRB determined that this research project does not meet the Department of Health and Human Services definition of human subjects research under 45 CFR 46 and, therefore, does not require IRB oversight. The project used de-identified data from UK Biobank as well as summary statistics from FinnGen and Biobank Japan. Details on ethical approval and oversight for these individual projects is as follows. UK Biobank’s scientific protocol and operational procedures have been reviewed and approved by the North West NHS research ethics committee. The UK Biobank resource is an approved Research Tissue Bank and is registered with the Human Tissue Authority, which means that researchers who wish to use it do not need to seek separate ethics approval (unless re-contact with participants is required). FinnGen was evaluated by the Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District. The research project complies with existing legislation (in particular, the Biobank Law and the Personal Data Act) and will conform to any new laws. The Biobank Japan Project was approved by the research ethics committees at the Institute of Medical Science, the University of Tokyo, the RIKEN Yokohama Institute, and the 12 cooperating hospitals. All participants gave written consent to participate in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this study were obtained from the UKBB through application 26041. All phenotypic data and array genotypes are accessible through application to UK Biobank. Currently, exome sequencing data for ∼200,000 participants is available; the remainder of the exome data is scheduled for public release in 2021.